![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RG Booth, SD Wyrick, RJ Baldessarini, NS Kula, AM Myers and RB Mailman
Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Chapel Hill 27599-7360.
Several novel phenylaminotetralins (PATs) cause functional changes in brain that are associated with binding to saturable, high affinity sites that are not identical to any known central nervous system receptor. These PATs were tested for their ability to cause receptor- mediated functional effects on tyrosine hydroxylase activity in corpus striatum from rat and guinea pig brain. (+/-)-(trans)-1-Phenyl-3- dimethylamino-6-chloro-7-hydroxy-1,2,3,4- tetrahydronaphthalene (CI, OH- PAT) increased tyrosine hydroxylase activity (by approximately 30-40%) at 0.1 microM. Higher concentrations inhibited enzyme activity by indirect mechanisms that may include displacement of intraneuronal dopamine. The 6,7-unsubstituted congener (+/-)-(trans)-1-phenyl-3- dimethylamino-1,2,3,4- tetrahydronaphthalene stimulated tyrosine hydroxylase by as much as 50-60% over basal activity, without displacement of dopamine. Similarly to certain (+)-benzomorphan sigma receptor ligands, the effects of both PATs to activate tyrosine hydroxylase were blocked competitively by the putative sigma antagonist BMY-14802. Radiolabeled [3H]CI,OH-PAT bound saturably and with high affinity to guinea pig brain membranes (Kd = 31 pm, Bmax = 6.5 fmol/mg of protein). The pharmacological profile of these binding sites was inconsistent with those of known sigma 1, sigma 2, dopaminergic, serotonergic, adrenergic, opioid, N-methyl-D-aspartate, or several other characterized central nervous system recognition sites. Together, these data suggest that these PATs may be agonists at a novel sigma- like site that has neuromodulatory activity that results in increases of brain catecholamine synthesis via activation of tyrosine hydroxylase.
This article has been cited by other articles:
|
|
 |
|
  T. R. Anderson, C. R. Jarvis, A. J. Biedermann, C. Molnar, and R. D. Andrew Blocking the Anoxic Depolarization Protects Without Functional Compromise Following Simulated Stroke in Cortical Brain Slices J Neurophysiol, February 1, 2005; 93(2): 963 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Booth, N. H. Moniri, R. A. Bakker, N. Y. Choksi, W. B. Nix, H. Timmerman, and R. Leurs A Novel Phenylaminotetralin Radioligand Reveals a Subpopulation of Histamine H1 Receptors J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 328 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Whittemore, V. I. Ilyin, and R. M. Woodward Antagonism of N-Methyl-D-Aspartate Receptors by sigma Site Ligands: Potency, Subtype-Selectivity and Mechanisms of Inhibition J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 326 - 338. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
